A promising outlook for diabetic kidney disease
- PMID: 30532022
- DOI: 10.1038/s41581-018-0092-5
A promising outlook for diabetic kidney disease
References
-
- Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 6, 691–704 (2018). - DOI
-
- Tuttle, K. R. et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 6, 605–617 (2018). - DOI
-
- Majumder, S. et al. Shifts in podocyte histone H3K27me3 regulate mouse and human glomerular disease. J. Clin. Invest. 128, 483–499 (2018). - DOI
-
- Thomas, M. C. & Cherney, D. Z. I. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia 61, 2098–2107 (2018). - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
